MYRIAD GENETICS INC's ticker is MYGN and the CUSIP is 62855J104. A total of 192 filers reported holding MYRIAD GENETICS INC in Q3 2022. The put-call ratio across all filers is 0.37 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $59,750,652 | +183.7% | 3,725,103 | +310.1% | 0.03% | +200.0% |
| Q2 2023 | $21,057,825 | +64381.8% | 908,448 | -35.4% | 0.01% | -44.4% |
| Q1 2023 | $32,657 | +52.9% | 1,405,791 | -4.5% | 0.02% | +50.0% |
| Q4 2022 | $21,365 | -99.9% | 1,472,416 | +14.4% | 0.01% | -14.3% |
| Q3 2022 | $24,547,000 | +852.5% | 1,286,535 | +807.3% | 0.01% | +600.0% |
| Q2 2022 | $2,577,000 | -79.3% | 141,800 | -71.4% | 0.00% | -71.4% |
| Q1 2022 | $12,474,000 | -69.4% | 494,987 | -66.5% | 0.01% | -65.0% |
| Q4 2021 | $40,758,000 | +91.4% | 1,476,745 | +123.9% | 0.02% | +53.8% |
| Q3 2021 | $21,298,000 | -22.9% | 659,591 | -27.0% | 0.01% | -23.5% |
| Q2 2021 | $27,630,000 | +0.3% | 903,520 | -0.2% | 0.02% | -10.5% |
| Q1 2021 | $27,559,000 | +12.3% | 905,063 | -27.1% | 0.02% | +5.6% |
| Q4 2020 | $24,536,000 | +68.8% | 1,240,748 | +11.3% | 0.02% | 0.0% |
| Q3 2020 | $14,534,000 | +2890.5% | 1,114,565 | +2500.0% | 0.02% | +1700.0% |
| Q2 2020 | $486,000 | -40.2% | 42,868 | -24.5% | 0.00% | -50.0% |
| Q1 2020 | $813,000 | -96.0% | 56,812 | -92.3% | 0.00% | -92.0% |
| Q4 2019 | $20,102,000 | -60.5% | 738,238 | -59.7% | 0.02% | -67.5% |
| Q2 2019 | $50,827,000 | +71.8% | 1,829,633 | +105.4% | 0.08% | +75.0% |
| Q1 2019 | $29,578,000 | +189.3% | 890,908 | +153.3% | 0.04% | +175.0% |
| Q4 2018 | $10,224,000 | -77.0% | 351,688 | -63.6% | 0.02% | -70.9% |
| Q3 2018 | $44,493,000 | +261.1% | 967,235 | +193.3% | 0.06% | +243.8% |
| Q2 2018 | $12,323,000 | +1001.3% | 329,754 | +771.2% | 0.02% | +1500.0% |
| Q1 2018 | $1,119,000 | -86.1% | 37,852 | -83.9% | 0.00% | -90.9% |
| Q4 2017 | $8,053,000 | -69.6% | 234,476 | -68.0% | 0.01% | -72.5% |
| Q3 2017 | $26,483,000 | -34.4% | 731,956 | -53.2% | 0.04% | -44.4% |
| Q2 2017 | $40,377,000 | +4.1% | 1,562,571 | -22.7% | 0.07% | +1.4% |
| Q1 2017 | $38,792,000 | +36.1% | 2,020,436 | +18.1% | 0.07% | +20.3% |
| Q4 2016 | $28,508,000 | -17.5% | 1,710,080 | +1.9% | 0.06% | +1.7% |
| Q3 2016 | $34,552,000 | +40.8% | 1,678,926 | +109.3% | 0.06% | +3.6% |
| Q2 2016 | $24,543,000 | +111.0% | 802,049 | +158.1% | 0.06% | +93.1% |
| Q1 2016 | $11,631,000 | +398.3% | 310,742 | +474.7% | 0.03% | +480.0% |
| Q4 2015 | $2,334,000 | +401.9% | 54,072 | +336.1% | 0.01% | +400.0% |
| Q3 2015 | $465,000 | +20.5% | 12,398 | +13.6% | 0.00% | 0.0% |
| Q1 2015 | $386,000 | -81.5% | 10,918 | -82.2% | 0.00% | -75.0% |
| Q4 2014 | $2,088,000 | +8.2% | 61,300 | +22.6% | 0.00% | -20.0% |
| Q3 2014 | $1,929,000 | +738.7% | 50,000 | +747.5% | 0.01% | +400.0% |
| Q2 2014 | $230,000 | -82.5% | 5,900 | -84.6% | 0.00% | -75.0% |
| Q1 2014 | $1,313,000 | -82.6% | 38,400 | -89.3% | 0.00% | -83.3% |
| Q4 2013 | $7,528,000 | -23.5% | 358,800 | -14.3% | 0.02% | -25.0% |
| Q3 2013 | $9,838,000 | +3915.5% | 418,635 | +4500.4% | 0.03% | +3100.0% |
| Q2 2013 | $245,000 | – | 9,100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 5,000,000 | $90,850,000 | 3.94% |
| Altium Capital Management LP | 221,000 | $4,016,000 | 1.61% |
| DISCIPLINED GROWTH INVESTORS INC /MN | 1,900,787 | $34,537,000 | 0.93% |
| Zebra Capital Management LLC | 15,352 | $279,000 | 0.82% |
| PFM Health Sciences, LP | 1,177,250 | $21,391,000 | 0.82% |
| EARNEST PARTNERS LLC | 6,462,138 | $117,417,000 | 0.78% |
| Glenview Capital Management | 1,696,791 | $30,831,000 | 0.77% |
| AIMZ Investment Advisors, LLC | 42,085 | $765,000 | 0.37% |
| Phocas Financial Corp. | 127,949 | $2,325,000 | 0.35% |
| Redhawk Wealth Advisors, Inc. | 34,680 | $630,000 | 0.29% |